Genomic Score Predicted Cancer Survival Benefit
Researchers developed a 70-gene model to estimate patient response to immune checkpoint inhibitor therapies.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Should medical breakthroughs be prioritized primarily by survival outcomes over other factors?
A new genomic score successfully predicted survival benefits for patients with neuroendocrine neoplasms receiving immune checkpoint inhibitors. The findings provide a potential tool for guiding treatment decisions in cases where no validated predictors previously existed.
Why it matters
Currently, clinicians lack validated benchmarks to determine which patients will respond favorably to immune checkpoint inhibitor therapy. This new scoring system helps identify patients likely to see improved survival outcomes from these specific cancer treatments.
The study utilized a score comprising 70 genes across 24 functional domains to analyze 54 patients. Investigators also validated the predictive power of the genomic score using a larger pan-cancer cohort of 1,661 patients.
The players
OSUCCC-James
The Ohio State University Comprehensive Cancer Center is a major research institution where the clinical study of 54 patients was conducted.
The Oncologist
The Oncologist is a peer-reviewed medical journal that published the findings regarding the genomic score for neuroendocrine neoplasms.
The details
The genomic score is calculated as the difference between positive and negative gene alteration scores. Patients achieving a score of 2 or higher experienced significant survival benefits compared to those who fell below this threshold.
Timeline
Patients were treated between 2017 and 2023.
The study was published in September 2026.
The Big Picture
This research follows a pattern set by the National Cancer Institute precision medicine initiative by using molecular data to personalize cancer care. The development of this score marks a departure from one-size-fits-all oncology protocols toward targeted genomic prognostic modeling.
This discovery could eventually provide oncologists with a reliable metric to determine if immunotherapy is the right course of action for a patient. By identifying likely responders early, the model may help avoid unnecessary treatments that offer little clinical benefit.
The takeaway
Predictive genomic scoring represents a major leap forward in managing difficult-to-treat neuroendocrine tumors. Patients should consult with their oncologists to see if genomic testing for immunotherapy markers is available at their treatment center.
Further reading
For more on advancements in oncology, visit the Cancer section.
More information
Read the full scientific study reference for detailed methodology.
Live Poll
Should medical breakthroughs be prioritized primarily by survival outcomes over other factors?
